Denali Therapeutics Inc. (FRA:4DN)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.50B +25.6% |
| Revenue (ttm) | n/a |
| Net Income | -436.53M |
| EPS | -2.53 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 177 |
| Open | 17.13 |
| Previous Close | 19.11 |
| Day's Range | 17.13 - 17.13 |
| 52-Week Range | 10.17 - 19.24 |
| Beta | n/a |
| RSI | 46.89 |
| Earnings Date | May 6, 2026 |
About Denali Therapeutics
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzym... [Read more]
News
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome Transcript
Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for...
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
Denali Therapeutics Inc. (DNLI) Presents at Stifel 2026 Virtual CNS Forum Transcript
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Denali Therapeutics Inc. (DNLI) Presents at TD Cowen 46th Annual Health Care Conference Transcript
FDA reversals leave investors worrying about the fates of other experimental drugs
The FDA in the past year has denied or discouraged applications of at least eight new drugs, according to RTW Investments. The agency initially refused to review Moderna's flu shot before reversing co...
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, an...
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
Denali Therapeutics Inc. (DNLI) Shareholder/Analyst Call Transcript
Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced data from programs in Hunter syndrome (mucopolysaccharidosis type II, MPS II), Sa...
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that management will host a live webcast to review presentations on its Enzyme Tr...
Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the presentation of clinical and preclinical data from its Enzyme TransportVehicl...
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
SOUTH SAN FRANCISCO, Calif., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced the publication of results from the open-label Phase 1/2 clinical trial of its in...
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment
Denali Therapeutics Inc. is maintained at a Strong Buy rating, driven by progress in its MPS II [Hunter Syndrome] program with tividenofusp alfa. Despite discontinuing ALS efforts, DNLI's BLA for tivi...
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the pricing of its underwritten public offering of 9,142,857 shares of its common...
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it intends to offer and sell $200 million of shares of its common stock and,...
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
SOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royal...
Denali: Regulatory Delay Is A Strategic Opportunity
Denali Therapeutics (DNLI) is transitioning from a clinical-stage to a commercial-stage biotech, leveraging its innovative blood-brain barrier Transport Vehicle platform. DNLI's financials reflect inc...
Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript
Denali Therapeutics Inc. ( DNLI) Jefferies London Healthcare Conference 2025 November 18, 2025 7:30 AM EST Company Participants Ryan Watts - Co-Founder, President, CEO & Director Alexander Schuth - C...
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2025, and provided bus...
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
The U.S. Food and Drug Administration extended on Monday Denali Therapeutics Inc.'s (NASDAQ:DNLI) review timeline of the Biologics License Application (BLA), seeking accelerated approval of tividenofu...
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that the U.S. Food and Drug Administration (FDA) has extended its review timeline...
Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Denali Therapeutics Inc. (NASDAQ:DNLI) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Ryan Watts - Co-Founder, President, CEO & Director Co...
The Best Small-Cap Stocks to Buy Now
Wall Street's best small-cap stocks to buy include biotech, real estate and software names.
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Tividenofusp alfa BLA for Hunter syndrome accepted for priority review and assigned PDUFA target action date of January 5, 2026; company preparing for commercial launch DNL126 accelerated approval pat...